| Identification | Back Directory | [Name]
Periplocoside | [CAS]
13137-64-9 | [Synonyms]
Periplocin
Periplocoside
3β-[(4-O-β-D-Glucopyranosyl-3-O-methyl-2,6-dideoxy-β-D-ribo-hexopyranosyl)oxy]-5,14-dihydroxy-5β,14β-card-20(22)-enolide
Card-20(22)-enolide, 3-[(2,6-dideoxy-4-O-β-D-glucopyranosyl-3-O-methyl-β-D-ribo-hexopyranosyl)oxy]-5,14-dihydroxy-, (3β,5β)- | [Molecular Formula]
C36H56O13 | [MDL Number]
MFCD01745141 | [MOL File]
13137-64-9.mol | [Molecular Weight]
696.825 |
| Chemical Properties | Back Directory | [Melting point ]
205°C | [alpha ]
D20 +32° | [Boiling point ]
610.7°C (rough estimate) | [density ]
1.1241 (rough estimate) | [refractive index ]
1.7500 (estimate) | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
DMSO : 250 mg/mL (358.77 mM; Need ultrasonic) | [form ]
powder | [pka]
12.89±0.70(Predicted) | [color ]
White | [Water Solubility ]
7.937g/L(cold water) |
| Hazard Information | Back Directory | [Uses]
Periplocin can be used to improve bone health to prevent, alleviate, or treat osteoporosis. | [in vivo]
Periplocin (5-20 mg/kg; intraperitoneal injection; daily; for 14 days; female SCID mice) treatment represses the growth of hepatocellular carcinoma (HCC) in xenograft tumor model in mice[2]. | Animal Model: | Female SCID mice (6-8 weeks old) injected with Huh-7 cells[2] | | Dosage: | 5 mg/kg, 20 mg/kg | | Administration: | Intraperitoneal injection; daily; for 14 days | | Result: | Repressed the growth of hepatocellular carcinoma (HCC) in xenograft tumor model in mice.
|
|
|
|